Cui Y, Wang M, Cheng A, Zhang W, Yang Q, Tian B
Front Microbiol. 2024; 15:1431672.
PMID: 39015737
PMC: 11250606.
DOI: 10.3389/fmicb.2024.1431672.
Monaco M, Idris O, Essani K
Cancers (Basel). 2023; 15(8).
PMID: 37190321
PMC: 10137028.
DOI: 10.3390/cancers15082393.
Tazzyman S, Stewart G, Yeomans J, Linford A, Lath D, Conner J
Viruses. 2023; 15(3).
PMID: 36992311
PMC: 10059747.
DOI: 10.3390/v15030603.
Li H, Li W, Zhang S, Qiu M, Li Z, Lin Y
Microbiol Spectr. 2022; 10(1):e0138821.
PMID: 34985336
PMC: 8729766.
DOI: 10.1128/spectrum.01388-21.
Apolonio J, Lima de Souza Goncalves V, Santos M, Silva Luz M, Silva Souza J, Rocha Pinheiro S
World J Virol. 2021; 10(5):229-255.
PMID: 34631474
PMC: 8474975.
DOI: 10.5501/wjv.v10.i5.229.
"Non-Essential" Proteins of HSV-1 with Essential Roles In Vivo: A Comprehensive Review.
Dogrammatzis C, Waisner H, Kalamvoki M
Viruses. 2020; 13(1).
PMID: 33374862
PMC: 7824580.
DOI: 10.3390/v13010017.
Herpes Simplex Virus 1 ICP34.5 Alters Mitochondrial Dynamics in Neurons.
Manivanh R, Mehrbach J, Charron A, Grassetti A, Ceron S, Taylor S
J Virol. 2020; 94(14).
PMID: 32376626
PMC: 7343198.
DOI: 10.1128/JVI.01784-19.
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.
Vajaitu C, Draghici C, Solomon I, Lisievici C, Popa A, Lupu M
J Immunol Res. 2018; 2018:4625472.
PMID: 30417020
PMC: 6207859.
DOI: 10.1155/2018/4625472.
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.
Keller H, Zhang X, Li L, Schaider H, Wells J
Oncotarget. 2017; 8(43):75675-75686.
PMID: 29088901
PMC: 5650456.
DOI: 10.18632/oncotarget.18523.
PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz.
Crespillo-Casado A, Chambers J, Fischer P, Marciniak S, Ron D
Elife. 2017; 6.
PMID: 28447936
PMC: 5429092.
DOI: 10.7554/eLife.26109.
Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.
Hughes T, Coffin R, Lilley C, Ponce R, Kaufman H
Oncolytic Virother. 2016; 3:11-20.
PMID: 27512660
PMC: 4918360.
DOI: 10.2147/OV.S36701.
Oncolytic viruses-immunotherapeutics on the rise.
Keller B, Bell J
J Mol Med (Berl). 2016; 94(9):979-91.
PMID: 27492706
DOI: 10.1007/s00109-016-1453-9.
Cancer immunotherapy: the beginning of the end of cancer?.
Farkona S, Diamandis E, Blasutig I
BMC Med. 2016; 14:73.
PMID: 27151159
PMC: 4858828.
DOI: 10.1186/s12916-016-0623-5.
Oncolytic viruses: a new class of immunotherapy drugs.
Kaufman H, Kohlhapp F, Zloza A
Nat Rev Drug Discov. 2015; 14(9):642-62.
PMID: 26323545
PMC: 7097180.
DOI: 10.1038/nrd4663.
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.
Ning J, Wakimoto H
Front Microbiol. 2014; 5:303.
PMID: 24999342
PMC: 4064532.
DOI: 10.3389/fmicb.2014.00303.
Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing.
Tang S, Guo N, Patel A, Krause P
J Virol. 2013; 87(10):5820-30.
PMID: 23487469
PMC: 3648131.
DOI: 10.1128/JVI.03500-12.
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Kanai R, Zaupa C, Sgubin D, Antoszczyk S, Martuza R, Wakimoto H
J Virol. 2012; 86(8):4420-31.
PMID: 22345479
PMC: 3318611.
DOI: 10.1128/JVI.00017-12.
Analyses of the spleen proteome of chickens infected with Marek's disease virus.
Thanthrige-Don N, Abdul-Careem M, Shack L, Burgess S, Sharif S
Virology. 2009; 390(2):356-67.
PMID: 19540544
PMC: 7103390.
DOI: 10.1016/j.virol.2009.05.020.
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.
Yu Y, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y
Mol Cancer Ther. 2009; 8(1):141-51.
PMID: 19139123
PMC: 2664310.
DOI: 10.1158/1535-7163.MCT-08-0533.
Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1.
Verpooten D, Ma Y, Hou S, Yan Z, He B
J Biol Chem. 2008; 284(2):1097-105.
PMID: 19010780
PMC: 2613634.
DOI: 10.1074/jbc.M805905200.